Riluzole
- Atc Codes:N07XX02
- CAS Codes:1744-22-5
- PHARMGKB ID:1744-22-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Rilutek; Belgium: Rilutek; Bulgaria: Rilutek; Czech Republic: Rilutek, Sclefic; Denmark: Rilutek; Estonia: Lizolorol, Rilutek, Riluzole, Sclefic, Zolerilis; Finland: Rilutek; France: Rilutek; Germany: Lizolorol, Rilutek, Riluzol, Rimipole, Zolerilis; Greece: Rilutek; Hungary: Rilutek, Sclefic; Ireland: Rilutek, Riluzole; Italy: Rilutek; Latvia: Rilutek, Riluzole; Lithuania: Rilutek, Riluzole; Luxembourg: Rilutek; Malta: Rilutek; Netherlands: Rilutek, Riluzol; Poland: Rilutek, Sclefic; Portugal: Rilutek, Riluzol; Romania: Rilutek, Sclefic; Slovakia: Rilutek, Sclefic; Slovenia: Rilutek; Spain: Rilutek; Sweden: Lizolorol, Rilutek, Riluzol; UK: Rilutek.
North America
Canada: Rilutek; USA: Rilutek, Riluzole.
Latin America
Argentina: Rilasat, Rilutek, Rizol; Brazil: Rilutek; Mexico: Rilutek.
Asia
Japan: Rilutek.
Drug combinations
Chemistry
Riluzole: C~8~H~5~F~3~N~2~OS. Mw: 234.20. (1) 2-Benzothiazolamine, 6-(trifluoromethoxy)-; (2) 2-Amino-6-(trifluoromethoxy)benzothiazole. CAS-1744-22-5 (1995).
Pharmacologic Category
Central Nervous System Agents, Miscellaneous; Glutamate Inhibitor. (ATC-Code: N07XX02).
Mechanism of action
Mechanism of action unknown. Pharmacologic properties include inhibitory effect on glutamate release, inactivation of voltage-dependent sodium channels, and ability to interfere with intracellular events which follow transmitter binding at excitatory amino acid receptors.
Therapeutic use
Treatment of amyotrophic lateral sclerosis. Riluzole can extend survival or time to tracheostomy.
Pregnancy and lactiation implications
Impaired fertility, decreased implantation, increased intrauterine death, and adverse effects on offspring growth and viability observed in animal studies. There are no adequate, well-controlled studies in pregnant women. Not recommended in nursing women.
Unlabeled use
Contraindications
Severe hypersensitivity reactions to riluzole or any component of the formulation.
Warnings and precautions
CNS depression may cause dizziness or somnolence. Use with caution in hepatic impairment (increased AUC in mild or moderate hepatic impairment). Rarely, jaundice reported. Use not recommended in baseline elevations of liver function tests (especially increased bilirubin). Neutropenia (ANC <500/mm^3^) reported rarely within first 2 months of therapy. May cause elevations in transaminases (usually transient). Use with caution in renal impairment, and in the elderly, females, and Japanese patients (decreased clearance).